Clinical trial NCT03365661: QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML
Official title: QUILT-3.034: Multi-Center Trial of Non-Myeloablative TCRa/b Deplete Haploidentical Hematopoietic Cell Transplantation With Post HCT ALT-803 in High-Risk Myeloid Diseases
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: High-Risk Acute Myeloid Leukemia
Treatment-Related Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Myelodysplastic Syndrome
Keywords: AML
MDS
Lead sponsor: Masonic Cancer Center, University of Minnesota
Sponsor class: OTHER
Collaborators: name: University of Minnesota
First posted: 2017-12-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase II multi-institutional therapeutic study of a non-myeloablative T cell receptor (TCR) alpha/beta depleted haploidentical transplantation with post-transplant immune reconstitution using ALT-803 for the treatment of high-risk myeloid leukemia (AML), treatment-related/secondary AML, and myelodysplastic syndrome (MDS).


Eligibility criteria: Inclusion Criteria:

* Age ≥18 to ≤70 years
* Meets one of the following disease and risk categories:

  * High-Risk Acute Myeloid Leukemia (AML) with predicted risk of relapse higher than 30%, which includes, but not limited to the following:

    * Patients in morphological remission (CR1 or beyond) with minimal residual disease as quantified either by flow cytometry, or by cytogenetics or molecular markers.
    * Patients with the following karyotypes in morphological CR or CRi: ELN-Intermediate I, Adverse, ELN-Intermediate-II. (18) (Examples include monosomal karyotype, complex karyotype, mutant p53, mutant RUNX1, mutant ASXL1, mutant FLT3-ITD, mutant DNMT3A, Inversion 3, T(6:9), KIT mutated core binding factor AML)
  * Treatment-Related AML and Secondary AML in morphological remission (CR1 or beyond) with minimal residual disease as quantified either by flow cytometry, or by cytogenetics or molecular markers
  * Myelodysplastic Syndrome (MDS) with \< 5% blasts by morphology and meets at least one of the following:

    * Received intensive induction chemotherapy (i.e. 7+3 or MEC) OR
    * Progression after 4 cycles of hypomethylating agents
  * The donor and recipient must be HLA identical for at least one haplotype (using high resolution DNA based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1
* Karnofsky performance status ≥ 60% (appendix IV)
* Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) defined as:

  * Hepatic: AST and ALT \< 3 x upper limit of institutional normal
  * Renal: estimated glomerular filtration rate (GFR) ≥ 40 mL/min/1.73m2
  * Pulmonary: oxygen saturation ≥ 90% on room air with no symptomatic pulmonary disease. If symptomatic or prior known impairment DLCOcor ≥ 40%.
  * Cardiac: LVEF ≥ 40% by echocardiography, MUGA, or cardiac MRI, no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
* Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to transplant (excluding preparative regimen pre-medications)
* Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy
* Voluntary written consent prior to the performance of any research related procedures

Exclusion Criteria:

* Acute leukemias of ambiguous lineage
* Allogeneic transplant for AML within the previous 6 months (no time limit for autologous transplant)
* Active CNS disease - if a history of AML related CNS involvement, screening CSF analysis must be negative
* Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening
* Active autoimmune disease requiring systemic immunosuppressive therapy
* History of severe asthma and currently on systemic chronic medications (mild asthma requiring inhaled steroids only is eligible)
* New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).
* Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
* Active concomitant second malignancy (i.e. has required treatment in the previous 6 months)
* Known hypersensitivity to any of the study agents
* Received any investigational drugs within the 14 days before 1st dose of fludarabine

Primary outcomes:
measure: Incidence of disease response
timeFrame: Day 28
Secondary outcomes:
measure: Disease Free Survival (DFS)
timeFrame: 12 months
measure: Treatment Related Mortality (TRM)
timeFrame: 12 months
measure: Disease Relapse
timeFrame: 12 months
measure: Grade II-IV acute Graft versus Host Disease (aGVHD)
timeFrame: Day 100
measure: Serious Adverse Events from ALT-803 (Early Schedule)
timeFrame: 1 Year
measure: Serious Adverse Events from ALT-803 (Late Schedule)
timeFrame: 1 Year
measure: Chronic Graft versus Host Disease (cGVHD)
timeFrame: 1 year
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Masonic Cancer Center
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Sarah Cooley, MD
role: PRINCIPAL_INVESTIGATOR
References: